Combinations of β-lactam antibiotics currently in clinical trials are efficacious in a dhp-i-deficient mouse model of tuberculosis infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4997-4999

  Rullas, Joaquín ^a,e   Dhar, Neeraj ^b,e   McKinney, John D ^b,e   García Pérez, Adolfo ^a,e   Lelievre, Joël ^a,e   Diacon, Andreas H ^e,f   Hugonnet, Jean Emmanuel ^c,d,e   Arthur, Michel ^c,d,e   Angulo Barturen, Iigo ^a,e   Barros Aguirre, David ^a,e   Ballella, Lluís ^a,e  

^a GLAXOSMITHKLINE   (Spain)

^b EPFL   (Switzerland)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d INSERM   (France)

^e Open Collaborative Model for Tuberculosis Lead Optimisation (ORCHID) Consortium Consortium   (France)

^f STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFDINIR; CLAVULANIC ACID; DEHYDROPEPTIDASE I; FROPENEM; MEROPENEM; MOXIFLOXACIN; PEPTIDASE; PROBENECID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAM; DIPEPTIDASE; DIPEPTIDASE 1; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; IN VIVO STUDY; INFECTION CONTROL; LUNG; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MOUSE MODEL; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; ANIMAL; C57BL MOUSE; COMBINATION DRUG THERAPY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DIPEPTIDASES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GPI-LINKED PROTEINS; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TUBERCULOSIS;

EID: 84940398610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01063-15     Document Type: Article

References (18)

1. Wang F, Cassidy C, Sacchettini JC. 2006. Crystal structure and activity studies of the Mycobacterium tuberculosis β-lactamase reveal its critical role in resistance to β-lactam antibiotics. Antimicrob Agents Chemother 50:2762-2771. http://dx.doi.org/10.1128/AAC.00320-06.
2. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. 1995. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 39:20-24. http://dx.doi.org/10.1128/AAC.39.1.20.
3. England K, Boshoff HIM, Arora K, Weiner D, Dayao E, Schimel D, Via LE, Barry CE, III. 2012. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 56:3384-3387. http://dx.doi.org/10.1128/AAC.05690-11.
4. Veziris N, Truffot C, Mainardi J-L, Jarlier V. 2011. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 55:2597-2500. http://dx.doi.org/10.1128/AAC.01824-10.
5. Donald PR, Sirgel FA, Venter A, Parkin DP, Van de Wal BW, Barendse A, Smit E, Carman D, Talent J, Maritz J. 2001. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 33:466-469. http://dx.doi.org/10.1080/00365540152029954.
6. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 26:874-877. http://dx.doi.org/10.1086/513945.
7. Hugonnet J-E, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218. http://dx .doi.org/10.1126/science.1167498.
8. Dhar N, Dubée V, Ballell L, Cuinet J, Hugonnet J-E, Signorino-Gelo F, Barros D, Arthur M, McKinney JD. 2015. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother 59:1308-1319. http://dx.doi.org/10.1128 /AAC.03461-14.
9. Lun S, Miranda D, Kubler A, Guo H, Maiga MC, Winglee K, Pelly S, Bishai WR. 2014. Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams. mBio 5(5):e01767-14. http://dx .doi.org/10.1128/mBio.01767-14.
10. Horita Y, Maeda S, Kazumi Y, Doi N. 2014. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors. Antimicrob Agents Chemother 58:7010-7014. http://dx.doi.org/10.1128/AAC.03539-14.
11. Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. 2011. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 30:812-813. http://dx.doi.org/10.1097 /INF.0b013e3182154b05.
12. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. 2013. Efficacy and safety of meropenem- clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 41:1386-1392. http://dx.doi.org/10.1183/09031936.00124312.
13. Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, Clumeck N. 2012. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 16:558-560. http://dx.doi.org/10.5588/ijtld.11.0414.
14. Keener AB. 2014. Oldie but goodie: repurposing penicillin for tuberculosis. Nat Med 20:976-978. http://dx.doi.org/10.1038/nm0914-976.
15. Knopp H, Sundelof JG, Haydu R, Kahan FM. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase I. Antimicrob Agents Chemother 22:62-70.
16. Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T, Okuda T, Matsumura H, Sunagawa M. 1992. Stability of meropenem and effect of 1,-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 36:1577-1579.
17. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. 2005. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 49:2816-2821. http://dx.doi.org/10.1128/AAC.49.7.2816 -2821.2005.
18. Habib GM, Shi ZZ, Cuevas AA, Guo Q, Matzuk MM, Lieberman MW. 1998. Leukotriene D4 and cystinyl-bis-glycine metabolism in membranebound dipeptidase-deficient mice. Proc Natl Acad Sci U S A 95:4859-4863. http://dx.doi.org/10.1073/pnas.95.9.4859.